Monte Rosa Therapeutics: Wells Fargo cuts target price to $25 from $27
GLUE•Wells Fargo cut its target price for Monte Rosa Therapeutics to $25 from $27.
Related News
Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
MRNA•
Mizuho raises Emerson target price to $190 from $180
EMR•
Airbnb: BofA Global Research raises price objective to $205 from $195
ABNB•
TELUS declares quarterly dividend of CAD 0.1875 per share
TU•
Bloomin' Brands tops Q3 revenue estimates on comparable sales, gift card breakage
BLMN•